Apitope announces that the first in human clinical trial for the treatment of Graves’ disease has been published as a ‘Success Story’ by the European Commission

HASSELT, Belgium, and CHEPSTOW, UK, 13 September 19 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announces that the first in human clinical trial for the treatment of Graves’ disease funded by the European Union (DAVIAD) has been published as a “Success Story” on the European Union website. The article entitled ‘ New treatment on the horizon for Graves’ disease’ can be viewed in the following link:

https://ec.europa.eu/research/infocentre/article_en.cfm?artid=50625